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Kathryn Maitland1,2Abstract
Over 90% of the world’s severe and fatal Plasmodium falciparum malaria is estimated to affect young children in
sub-Sahara Africa, where it remains a common cause of hospital admission and inpatient mortality. Few children will
ever be managed on high dependency or intensive care units and, therefore, rely on simple supportive treatments
and parenteral anti-malarials. There has been some progress on defining best practice for antimalarial treatment
with the publication of the AQUAMAT trial in 2010, involving 5,425 children at 11 centres across 9 African countries,
showing that in artesunate-treated children, the relative risk of death was 22.5% (95% confidence interval (CI) 8.1
to 36.9) lower than in those receiving quinine. Human trials of supportive therapies carried out on the basis of
pathophysiology studies, have so far made little progress on reducing mortality; despite appearing to reduce
morbidity endpoints, more often than not they have led to an excess of adverse outcomes. This review highlights
the spectrum of complications in African children with severe malaria, the therapeutic challenges of managing
these in resource-poor settings and examines in-depth the results from clinical trials with a view to identifying the
treatment priorities and a future research agenda.
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In many parts of the world malaria incidence has de-
clined, in part due to substantial donor investment tar-
geting the scaling up of insecticide-treated nets (ITN)
and other vector control measures. Nevertheless, in 2010
it was estimated that there were 500 million episodes of
Plasmodium falciparum malaria each year [1,2]. In the
same year, the World Health Organization (WHO) esti-
mated that there were approximately 650,000 deaths di-
rectly attributed to malaria worldwide [3]. The heaviest
burden of P. falciparum malaria falls on sub-Saharan
Africa (sSA), where children under five years old are dis-
proportionately affected by this parasite (Figure 1). Today,
57% of Africa’s populations still live in areas with moder-
ate to high malaria transmission. Ten countries account
for 87% of people exposed to the highest malaria endemic-
ities globally, where the P. falciparum rates in children
two- to ten-years old exceed 50%. Malaria, therefore, re-
mains a very common cause of hospital admission in sSA,Correspondence: k.maitland@imperial.ac.uk
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unless otherwise stated.and where severe malaria is mainly a disease of children
under five years of age. It has been estimated that approxi-
mately 90% of the world’s severe and fatal malaria affects
young children in sSA [4,5].
Severe malaria is a complex multisystem disorder with
a clinical presentation that has many similarities to
severe bacterial sepsis, despite distinctive differences in
pathogenesis. Children typically present when they are
critically ill with life-threatening complications yet, in
most African hospitals, few will ever be managed on an
intensive care unit or in a high dependency facility. The
high, and frequently seasonal, burden of cases of severe
malaria presents a unique challenge to health services
and clinicians working in resource-limited hospitals. This
review intends to provide an overview of the spectrum
and complications of severe malaria, highlighting treat-
ment priorities for children managed within low-resource
settings in Africa and re-examining what has been learnt
from clinical trials to outline a future research agenda. In
order to contextualise the current and future relevance of
this review and the continued necessity to prioritise re-
search funding for this condition, I will briefly summarise
the current status of malaria eradication efforts, aimed ats is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 2010 World Map Plasmodium falciparum parasite rate in 2-10 year olds.
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ingly, if successful and sustained, negating the necessity
for future investment in this clinical disease.
Malaria control: are we nearly there yet?
The global strategy towards gradual malaria eradication
which has been developed and ratified into policy was
reviewed in 2010 in a four-part Lancet series [6-9]. It
focuses on aggressive control of transmission and invest-
ment in vaccine development, insecticides, new treat-
ments and diagnostics. Hospital admissions and deaths
due to malaria are, therefore, important barometers for
the effectiveness of these measures to control and elimi-
nate malaria. Substantial reductions have been witnessed
in several African countries, in some cases directly or
plausibly linked to the scaling up of control efforts
[10-14]. However, many of the encouraging reports have
tended to be from areas with relatively low baseline mal-
aria transmission intensities. In some cases, the greatest
decline in malaria hospitalisation preceded the scale-up of
ITN use or the introduction of artemisinin combination
therapies [13], suggesting that more complex mecha-
nisms are involved. Other sSA countries have documen-
ted either no decline in severe or fatal malaria [4], anincrease in hospitalisations during the same period [15,16]
or a resurgence following sustained control [17]. The
downstream effects on the spectrum of severe malaria
are uncertain, although there are reports that cerebral
malaria is now being witnessed in children over five
years old, in areas where it was previously rare (KM verbal
communication).
With regard to vaccine development, immunological
and clinical data from large Phase III multicentre vaccin-
ation trials of the most promising candidate on the mar-
ket to date (RTS,S), a vaccine which is directed against
the pre-erythrocytic stage of P. falciparum malaria, were
encouraging. However, longer term follow-up indicated
these responses were imperfect and short-lived. In the
18 months following vaccination with RTS,S, vaccine ef-
ficacy (VE) against clinical malaria in children was 46%
(95% confidence interval (CI) 42% to 50%) but only 27%
(95% CI 20% to 32%) in infants vaccinated between 6- and
12-weeks old [18,19]. VE waned with time in both groups
and VE was more notable at sites with a lower baseline in-
cidence of malaria [20]. Although further results of the
long term follow up are expected, in essence, this is the
status of malaria vaccine research and the culmination of
over 20 years of development and clinical trials.
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Formerly, severe malaria in African children was consid-
ered to comprise two distinct clinical syndromes: cere-
bral malaria and severe malarial anaemia. This paradigm
was supported by clinical, molecular, immunological and
genetic studies and, indeed, substantially influenced their
experimental design. As a consequence, it was held that
most malaria deaths were attributable to cerebral mal-
aria and, thus, were primarily neurological in origin, with
a smaller number resulting from severe malarial an-
aemia, which could be mitigated by an immediate blood
transfusion. Over the last three decades substantial re-
search funding has enabled much clearer and detailed
clinical phenotyping of severe malaria in African chil-
dren, its pathophysiology and complications. What has
been determined is that severe malaria encompasses a
complex syndrome affecting many organs resulting in
biochemical and haematological derangements which have
many features in common with the pathophysiological
derangements complicating children with severe sepsis.
Moreover, in-hospital deaths, most occurring within 24
hours of admission, appear to be a consequence of a
wide spectrum of pathophysiological determinants. At
the clinical level, a key challenge for health services in
Africa, owing to the large burden of paediatric admissions
with P. falciparum malaria infection, is distinguishing
those who are at greatest risk of poor outcome, using
largely clinical criteria, in order to target parenteral anti-
malarials and supportive therapies [21]. This is reviewed
in the next section.
Case definitions and defining those at greatest risk
Differentiating ‘true cases’ of severe malaria from other
acute infections remains both a clinical and epidemio-
logical challenge, as most symptoms of malaria are indis-
tinguishable from other major causes of morbidity, in
malaria-endemic sSA where parasite carriage is the norm
rather than the exception. For example, a child with se-
vere respiratory distress and P. falciparum malaria could
either have severe malaria or very severe pneumonia, an
issue that has been covered in a number of publications
[22-26]. Determining the cases at greatest risk of poor out-
come has been helped by a number of seminal papers. A
prospective study of 1,844 paediatric hospital admissions
with P. falciparum malaria in Kenya established that
two clinical features, impaired consciousness (defined
as coma or prostration) and respiratory distress (a clin-
ical sign of metabolic acidosis), identified 84% of fatal
cases. Prostration (the inability to sit upright in chil-
dren over eight months or breast feed), any respiratory
distress, hypoglycemia, jaundice, or any combination of
these, predicted 92% of fatal cases. Relevant to the trad-
itional severe malaria paradigm was that severe malarial
anaemia (defined as a haemoglobin (Hb) <5 g/dl) in theabsence of these two clinical signs had a very low mortal-
ity (1.3%) [27]. Similar findings were reported in Gambian
children with severe malaria where neurological status
(coma with or without extensor posturing), tachycardia,
tachypnoea, hypoglycemia and hyperlactatemia (plasma
lactate level, >5 mmol/L) were found as independent indi-
cators of a fatal outcome [28]. Using data from six re-
search units in Africa (SMAC network) the Lambaréné
Organ Dysfunction Score was developed, which combines
three variables: coma, prostration and deep breathing. The
scores ranged from 0 to 3. Sixty-one percent of the chil-
dren had none of the three signs, 26% had one, 10% had
two and 3% had all three signs (case fatality rate 36%).
However, it was unclear how the score was constructed
since, at an individual level, prostration and coma are mu-
tually exclusive, thus impossible to score 3 [29]. Probably
one of the most comprehensive descriptions of the clinical
and laboratory complications of severe malaria (and a sub-
sequent evaluation of prognostic markers) comes from the
large Phase III randomised clinical trial comparing artesu-
nate and quinine (African Quinine Artesunate Malaria
Trial: AQUAMAT) [30]. AQUAMAT included 5,425 par-
ticipants and was conducted in 11 centres across nine
countries, spanning East, West and Central sSA, thus
covering a range of malaria transmission intensities.
Baseline characteristics included severe acidosis (base
excess < −−‐8; 43%), coma (37%), convulsions (32%), se-
vere anaemia (Hb <5 g/dl; 30%), hypoglycaemia (blood
sugar level <3 mmol/L; 10%) and compensated shock
(9%). In a subsequent sub-analysis of the AQUAMAT
data which investigated predictors of poor outcome,
four parameters (out of 20 indicators of severity) were
identified that were independently associated with
fatality in a multivariate analysis [31]. These were base
deficit (>8 mmol/L), coma, elevated blood urea nitro-
gen (BUN, >20 mg/dL) and underlying chronic illness.
In those with coma and acidosis, case fatality was 23%,
in children with a combination of coma, acidosis and
raised BUN, mortality was 43% (Figure 2). Finally, since
asymptomatic carriage of parasites is common in en-
demic areas, a further refinement aimed at improving
the specificity of the case definition for either epidemio-
logical or research purposes proposed the addition of a
parasitaemia threshold [32]. The malarial-attributable case
fraction (MAF) for children with clinical evidence of se-
vere disease increased from 85% to 95% with the inclusion
of a parasitaemia threshold of over 2,500c parasites/ml
and with the exclusion of those presenting with malaria
parasites but had a primary diagnosis of gastroenteritis with
severe dehydration, pneumonia, culture-proven bacteraemia,
or meningitis.
The latest WHO guidelines [21], informed by syste-
matic reviews by the expert advisory group, have drawn
on these resources to inform clinical and therapeutic
Figure 2 Combinations of presentations and the associated mortality in children in the AQUAMAT trial. Venn diagram illustrating the
combinations of presentations and associated mortality from von Seidlein et al. 2012 [31].
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son of the clinical spectrum of malaria in adults and
children largely using the AQUAMAT data set [30] and
adult data from the corresponding artesunate-quinine
trial (SEAQUAMAT) conducted in southeast Asia [33]
(Table 1).
Severe malaria: the clinical syndromes and complications
Cerebral malaria
Neurological involvement is common in African chil-
dren. Typically, children with cerebral malaria present
with a history of a febrile illness lasting one to three days
with convulsions, impaired consciousness, with or without
brain-stem signs. This is strictly defined as an unrousable
coma that persists for more than one hour following a
seizure (irrespective of anticonvulsant medication) since
many children with malaria regain full consciousness after
a brief convulsion. The most widely used paediatric classi-
fication of impaired consciousness in sSA is the Blantyre
Coma Scale (BCS), a practical tool developed for children
who are too young to speak [34,35]. Coma is classified as
a BSC of 2 (out of a possible 5) or less. The precision ofthe clinical diagnosis of cerebral malaria, optimal for inter-
vention studies, has been shown to be considerably im-
proved by ophthalmoscopy (in temporarily-dilated pupils)
to assess for malaria retinopathy [36]. The observation of
a specific malaria retinopathy is supported by autopsy evi-
dence of intracerebral parasite sequestration in a study of
27 Malawian children with fatal cerebral malaria [37].
Neuroimaging data describing the changes associated
with cerebral malaria in African children remains very
limited. The only prospective study using magnetic res-
onance imaging (MRI) involved 120 Malawian children
with cerebral malaria (strictly defined as a BCS ≤ 2 plus
positive retinopathy on ophthalmoscopy) [38]. It identi-
fied the most common pathological finding as an abnor-
mal T2 signal in the basal ganglia (84%). In addition,
cerebral volume was moderately-severely increased in
nearly 50%, supporting evidence from previous autopsy
data, which until this study remained inconclusive owing
to the possibility that the findings could not exclude
post-morbid changes. Potential mechanisms for increased
volume suggested including parasite sequestration [37],
venous congestion [39] or ischemic (due to seizures) and
Table 1 Comparison of the typical signs and symptoms of severe malaria in South East Asian adults and in African
children
Sign or symptom Children Adults
Duration of illness Short 1–2 days Longer 5–7 days
Respiratory distress/deep breathing (acidosis) Common Common
Convulsions Common > 30% Common (12%)
Abnormal Motor Posturing Common Uncommon
Prostration/obtundation Common Common
Resolution of coma Early 1–2 days Longer 2–4 days
Neurological sequelae (following cerebral malaria) Common (5-30%) Uncommon (1%)
Jaundice Uncommon Common
Hypoglycaemia (blood glucose <2.2 mmol/L) Common Less common
Metabolic acidosis (base excess < -8; lactate > 5 mmols/L Common Common
Pulmonary oedema Rare Uncommon
Renal failure Rare Common
CSF opening pressure Usually raised Usually normal
Bleeding/clotting disturbances Rare Up to 10%
Invasive bacterial infection (co-infection) Common (10%) Uncommon (<5%)
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uncal or cerebellar herniation in nearly 10% [38], an unex-
pected finding since previous autopsy studies indicated
that evidence of herniation was uncommon [37]. Clinic-
ally, papilloedema (a putative clinical sign of raised intra-
cranial pressure) is considered uncommon in children
with severe malaria. This is supported by a review of oph-
thalmoscopic findings from 436 children prospectively re-
cruited into several studies of cerebral malaria in Kenya,
Malawi and The Gambia [36]. Bilateral swelling of the
optic nerve heads occurred in only 6% in marked contrast
to the very prevalent retinal changes. Of note, in over 50%
of children with papilloedema there was no other abnor-
mality in the fundus; however, prognosis with this sign
was very poor.
Seizures are the most common neurological complica-
tion of acute P. falciparum malaria, manifesting as either
simple tonic-clonic or partial convulsive episodes [40] to
clinically silent electrical status [41], which may or may
not be clinically detected as excess salivation and/or an
irregular respiratory pattern [42]. Overall, 38% of Kenyan
children had a history of seizures or evidence of seizures
at admission to hospital. Multiple seizures occurred in
over 50% of these cases, with 22% having a prolonged
seizure episode (>30 minutes). The peak prevalence of
seizures (49%) occurred in children 27- to 33-months
old and were generally associated with a shorter dur-
ation of illness and higher P. falciparum malaria parasit-
aemia [43]. Whilst short-lived seizures frequently occur
in young children with febrile illnesses, and have limited
prognostic significance, whether these are specifically
related to acute malarial illness was explored in a paperexamining the MAF. Children admitted with two or
more seizures in 24 hours prior to admission had very
high MAFs, suggesting that acute malaria was the chief
cause of convulsions [44].
In addition to seizures, abnormal motor posturing
(AMP) is also a common complication of children with
cerebral malaria, manifesting as generalised extension
of the trunk, increased muscular tone and posturing in
the upper and lower limbs and clinically characterised
as de-corticate, de-cerebrate or opisthotonic posturing.
Whilst the aetiology and pathogenesis remains poorly
understood, Idro and colleagues attempted to define
the burden and the prognosis of each type of posturing.
In 417 Kenyan children with cerebral malaria, 163 (39.1%)
had posturing during hospital stay, with 50% developing
AMP after admission [45], indicating a higher prevalence
than previously described since previous studies mainly
reported this complication at the point of admission. De-
corticate posturing was the commonest manifestation oc-
curring in 80 (49%), de-cerebrate AMP in 61 (37%) and
opisthotonic posturing in 22 patients (14%). Case fatality
rate was high in those with AMP (31; 19%), with the ter-
minal mode of death in 19 (61%) suggestive of trans-
tentorial herniation. Posturing was associated with age
over three years but not with any of the markers of se-
verity, except for opisthotonic posturing which was in-
dependently associated with severe metabolic acidosis.
Seizures after admission were more common in those
with de-cerebrate and opisthotonic manifestations.
Outcome for cerebral malaria remains poor with high
in-hospital mortality and neurological sequalae in sur-
vivors. In the AQUAMAT trial the subgroup with the
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all mortality of 359/1,825; 19.6% [30]. Outcome was no
better in the artesunate-treated children (18%) than in the
quinine-treated children (21%). Estimates of the preva-
lence of neurological sequelae deficits in survivors of cere-
bral malaria vary [46-48]. To counter this, a meta-analysis
was conducted including studies which had similar case
definitions of cerebral malaria, indicating that sequelae oc-
curred in approximately 11% [49]. The most common
neurological sequelae reported were ataxia (43%), hemi-
plegia (39%), speech disorders (39%), blindness (30%),
and cognitive [50,51] and behavioural abnormalities [52].
Some of the deficits were transient (for example, ataxia)
and fully resolved, whereas others showed improvement
over months (for example, hemiparesis) but did not fully
resolve [53]. A history of previous seizures, deep coma
and focal neurological signs observed during admission
were independent risk factors associated with persisting
impairments [54].
Severe anaemia
Severe anaemia in children in sSA remains a leading
cause of hospital admission [55] and a major factor in
the 800,000 malaria deaths/year [56]. It is a common pre-
senting feature of severe P. falciparum malaria in African
children, particularly young infants in high transmis-
sion settings. It is caused by haemolysis of both infected
and uninfected erythrocytes and exacerbated by im-
paired erythropoiesis [57]. Within international guidelines
(WHO) and across different African countries there are
some discrepancies with respect to the definition of severe
anaemia (and, thus, the threshold haemoglobin or haem-
atocrit level at which transfusion is recommended), some
defining severe anaemia as Hb <5 g/dl whereas others use
Hb <6 g/dl. For research definitions, severe malarial an-
aemia is defined as Hb <5 g/dl in recent guidelines (with
parasitological evidence of malaria infection) [58].
In terms of prognosis, since the prevalence of pre-
morbid chronic mild to moderate anaemia is very com-
mon in these populations, presentation in the absence of
any other complications has a lower MAF [32] and car-
ries a good prognosis with a case-fatality of <1% [27].
However, if combined with a parasitaemia of ≥2,500 the
MAF increases to over 90% [32]. It is also important to
note that, in addition to those presenting with severe
anaemia, this complication may also develop during
hospital admission especially in children with hyperpar-
asitaemia [59], hence the frequent need to monitor Hb.
The presence of respiratory distress increases case fa-
tality (approximately 15%) rising to 40% if also compli-
cated by impaired consciousness [27,60]. Although
timely transfusion can be life-saving, access to adequate
supplies of blood for transfusion remains a key chal-
lenge in sSA. In order to preserve this scarce resource,guidelines developed by the WHO encourage the ra-
tional use of blood transfusion and recommend that
transfusion be reserved for children with profound an-
aemia (Hb ≤4 g/dL) or for those with a Hb between 4
to 6 g/dL who have additional severity critieria in areas
where malaria is hyperendemic but suggest a higher
transfusion threshold of 7 g/dl in areas of low malaria
transmission [21]. Guideline-adherence remains poor
and hampered by the lack of clinical evidence that this
policy is safe in both the short and long term. It has
been shown that 63% of the early deaths occur in chil-
dren awaiting transfusion [61-63]. Furthermore, WHO
guidelines recommend a standard volume of 20 ml/kg
of whole blood (or 10 ml/kg packed cells) for any level
below 5 g/dl; however, in practice this results in only a
modest Hb rise of mean 2.5 to 3.3 g/dl following initial
transfusion with approximately 25% remaining severely
anaemic (<5 g/dL) [61]. High case fatalities of children
with severe malaria anaemia has resulted in recommen-
dations that the current transfusion guidelines be
evidence-based and tested in a clinical trial [64,65].
Metabolic acidosis and respiratory distress
Improved diagnostic capabilities have led to a better un-
derstanding of the importance of metabolic acidosis as a
common complication of severe malaria, despite its clin-
ical correlates (deep ‘Kussmaul’ breathing) being recog-
nised for decades [10,19]. Historically, respiratory distress
in children with severe malaria has been considered syn-
onymous with congestive cardiac failure [66], although
recent work suggests that heart failure is rare, whereas
deep breathing or metabolic acidosis [67] is central to
the pathophysiology. Moreover, clinical examination find-
ings and chest radiographs are usually normal, providing
further evidence that pulmonary oedema or ‘acute respira-
tory distress syndrome’ is rare in children, although com-
mon in adult severe malaria [21].
Despite being a common complication of severe malaria,
the aetiology of malarial acidosis is not well understood.
At a clinical level metabolic acidosis is more frequent in
children with severe anaemia [23], hypovolaemia [21], al-
tered rheological properties of non-parasitised red blood
cells (npRBCs) [24] and hepatic or renal dysfunction (due
to decreased elimination) [16,25,68]. Both increased pro-
duction and impaired metabolism of lactate [20] and
ketoacids [14,21,22] have been implicated as causes; how-
ever, other unidentified organic acids also contribute
[21,69,70]. Use of sodium bicarbonate to correct acid-
osis has fallen out of favour, largely since it failed to
address the underlying processes and conferred no clin-
ical benefit [27]. Treatment of acidosis with signs of
hypovolaemic shock is covered later in the clinical trials
section (see Fluid and vasopressin use for correction of
acidosis and shock). Current management guidelines
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anaemia with a blood transfusion, intravenous fluids at 3 to
4 ml/kg/hour (maintenance) and careful monitoring [21].
Hypoglycaemia
Hypoglycaemia is an important complication of severe
P. falciparum malaria, especially in children and preg-
nant women. Ten percent of children enrolled in the
AQUAMAT trial had hypoglycaemia (glucose <3 mmol/L)
at the point of admission [30] whereas other studies in
African children report higher frequencies at and during
the course of admission [71-74]. Hypoglycaemia is
independently associated with poor outcome [27,53,75],
specifically an increased mortality [28,71,76,77], predom-
inantly when accompanied by acidaemia (pH <7.3) or
hyperlactataemia (lactate >5 mmol/l) [60,73]. If not care-
fully monitored, hypoglycaemia can go unnoticed leading
to neurological impairment and neurological sequelae
[47,54,75]. The aetiology is incompletely understood and
is likely to be multifactorial. Depletion of glucose stores
due to starvation, parasite utilisation of glucose and
cytokine-induced impairment of gluconeogenesis have
been implicated [78]. Hyperinsulinaemia, secondary to
quinine therapy, has been advanced as an iatrogenic cause
and is well established in adults [79,80]. Data on its rela-
tionship in African children with severe malaria are rela-
tively few, but what does exist indicates that insulin levels
are appropriately low during episodes of hypoglycaemia,
either at admission or during quinine treatment [74,81].
In clinical practice there are several definitions of
hypoglycaemia, each targeting a different blood glucose
threshold. In adults and children hypoglycaemia defined as
a blood glucose of <2.2 mmol/L has been shown to be asso-
ciated with a poor outcome [81] and, hence, this definition
is incorporated as the research case definition of severe
malaria (for epidemiological and research purposes) [21].
Paediatric treatment guidelines indicate a blood glucose of
<3 mmol/L [82], which is now incorporated in the latest
2012 WHO severe malaria guidelines as the threshold for
intervention [21]. A retrospective study examining the out-
come across the range of blood glucose in 418 Malian chil-
dren with severe malaria found a 61.5% case fatality at a
glucose level of <2.2 mmol/L and 46.2% in those with low
glycaemia (blood glucose 2.2 to 4.4 mmol/L) compared to
13.4% in those with normoglycaemia (4.5 to 8.2 mmol/L)
[83]. The authors concluded that 6.1 mmol/L is an
optimum threshold for intervention, which is substantially
higher than currently recommended [58]. The poor out-
comes of children at higher glucose levels (up 4.0 mmol/L)
were also noted in a general admission population of
Kenyan children in whom this was found associated with
increased odds of mortality compared to all levels of glu-
cose concentration above this threshold [84]. Risk factors
associated with hypoglycaemia (glucose ≤3 mmol/l) atbaseline and subsequent development of hypoglycaemia
was examined in a retrospective review of 1,234 cases of
severe P. falciparum malaria [85]. Included in the study
were 952 children admitted to hospital before and 282
children admitted after the introduction of the new WHO
quinine regimen (when a loading dose of quinine was
increased from 10 mg/kg to 20 mg/kg). At baseline (and
before use of quinine) hypoglycaemia was present in 16%
of the initial cohort and 9% of the second cohort.
Following admission (and initiation of intravenous quinine
therapy), 15% developed one or more episodes of
hypoglycaemia, with over 70% of episodes occurring
within 24 hours of admission. There was no evidence of a
relationship between quinine dose and any degree of
hypoglycaemia after admission. Admission characteristics
that predicted later hypoglycaemia were hypoglycaemia,
severe anaemia and temperature gradient (a marker of
impaired perfusion). Hypoglycaemic episodes were more
common during transfusions or periods of disruption of
intravenous glucose infusion. Overall, fatal outcome was
more common in children developing hypoglycaemia after
admission (case fatality 24%) than their euglycaemic
counterparts (8%) [85].
As in sepsis, dysregulation of the cortisol, insulin,
mitochondrial, or other metabolic pathways have been
implicated in the aetiology of hypoglycaemia and deserve
further investigation. The evidence supporting the cur-
rent threshold suggests that intervention at a higher cut-
off maybe warranted but this needs to be tested in an
adequately powered clinical trial directly investigating
the optimum threshold for treating hypoglycaemia and
the best mode of treatment (dextrose loading or infusion).
Evidence for renal involvement in African paediatric
severe malaria
Renal involvement in severe malaria is common in adult
non-immune case series and semi-immune cases in south-
and southeast Asia (around 25% to 50% across various
series). Patients may progress to acute kidney injury with
anuric or oliguic renal failure [86]. However, in paediatric
severe malaria acute renal impairment has been assumed
to be minimal [87], but the piecemeal accumulation of data
now suggests this problem has been under-recognised.
Studies examining prognostic risk factors in Gambian chil-
dren with severe malaria noted that biochemical evidence
of hepatic and renal dysfunction were important additional
markers of a poor prognosis, but, contrary to the adult ex-
perience in severe malaria, none developed acute renal fail-
ure [28]. Several large clinical studies have confirmed the
independent significance of raised BUN (>20 mg/dl) or
creatinine (>80 mmols/L) and acidosis as poor prognostic
signs in severe malaria in African children [31,60]. BUN
and pH are measures of hypovolaemia or dehydration but
also reflect decreased elimination due to impaired renal
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incorporated in the Risk Injury Failure Loss End-Stage
(RIFLE) classification of acute kidney injury [88]. A
prospective study in Kenyan children [60] showed that
an elevated creatinine (>80 mmols/L) complicated 96/
469 (20%) cases at admission and was associated with a
case fatality of 26%. In the same study, four factors
were independently associated with fatal outcome (deep
‘acidotic’ breathing, hypoxia (SaO2 < 90%), hypoglycaemia
(<2.5 mmol/L) and creatinine >80 mmol/L (the odds ratio
for mortality with elevated creatinine was 5.76 (95% CI 2.3
to 14.3) P = 0.0002). In the AQUAMAT trial 1,009/4,148
(24%) had a BUN >20 mg/dL [30] and this parameter was
established as one of the three independent clinical fea-
tures predicting fatal outcome, together with acidosis and
impaired consciousness/convulsions [31]. The mortality in
children with all three predictors was 43% (Figure 2). In
the FEAST trial BUN >20 mg/dL was present on admis-
sion in 444/2,118 (21%), with prevalence varying across
the sites, being more frequent in hyperendemic areas of
Eastern Uganda 265/1,037 (25.6%) and less frequent in
Kilifi, Kenya where malaria is mesoendemic (25/189
(13.2%) [89] (KM, unpublished data).
The aetiology of renal injury in the paediatric kidney is
unknown and may reflect multiple insults including
hypovolaemia or dehydration (pre-renal failure) and dir-
ect tubular or glomerular injury. Pathological studies in
adults with severe malaria have shown sequestration of
parasitised red cells in glomerular and tubulo-interstitial
vessels and acute tubular damage due to accumulation
of monocytes in glomerular capillaries. The level of se-
questration in the kidney was greater in those who de-
veloped renal failure than in fatal cases without renal
failure [90]. No equivalent autopsy data are available
for African children. WHO malaria treatment guide-
lines consider acute kidney injury as a serum creatinine
level >250 mmol/L in adults [91] but does not indicate
any criteria for children. Guidelines for the diagnosis
and treatment of renal involvement are needed, as is ra-
tional integrated fluid management and other support-
ive treatment in paediatric malaria [87], which do not
currently exist.
Haemoglobinuria
Haemoglobinuria, or blackwater fever (BWF), a syn-
drome comprising acute intravascular haemolysis, fever
and the passage of dark- or red-coloured urine, in pa-
tients with current or recent malaria infection, is recog-
nised as a potential complication of malaria. Classically,
it was noted to be a consequence of long term use of
quinine in non-immune expatriates [92-94]. In African
children BWF is considered as a rare complication of
malaria [27,28,91,95], which is now supported by data
from the AQUAMAT trial [30]. BWF was reported inonly 237/5,426 (4.4%) with a case fatality rate similar
to the rest of the trial participants (22 deaths: 9.3%)
[31]. The development of haemoglobinuria in children
after admission, irrespective of treatment arm, was also
rare, <1%. A prospective study of severe malaria in chil-
dren in Papua New Guinea, reported the presence of
BWF, attributable to the passage of haemoglobin and/
or myoglobin (suggesting muscle breakdown) in the
urine, but found no association with glucose-6-phosphate
dehydrogenase (G6PD) deficiency [96]. In Vietnam, in a
case series of semi-immune adults with BWF, in which
only 32% had concurrent P. falciparum malaria infection,
aetiological factors included quinine treatment (56%) and
G6PD deficiency (54%) [97]. In Africa, recent publications
describing case-series of BWF tend to be from regions
where children are exposed to intense P. falciparum mal-
aria transmission (Nigeria, Democratic Republic of Congo
(DRC), and Uganda) [98-100]. In a case-control study
conducted in the DRC, the majority (88.4%) of BWF cases
occurred in the rainy season when BWF was apparently
more likely to be related to quinine pre-treatment. In this
series, seven children (16.2%) developed acute renal failure
[98]. In Nigerian children, a study of severe malaria re-
ported that haemoglobinuria (defined by dip-stick testing
of urine) occurred in 48/251 (19.1%), was commonly asso-
ciated with clinical jaundice (28/48, 58.3%) and that 6%
developed renal failure [100]. Unlike the G6PD variants in
southeast Asia the African variant (A-) is a mild variant,
with most males retaining 20% of normal G6PD activity,
sufficient to protect carriers from side-effects of oxidizing
drugs or food products. G6PD deficiency is, therefore, un-
likely to be a major cause of BWF; if it were, then one
would expect that BWF would be more widely reported as
a common complication of malaria owing to the high
population frequencies in sSA, where it is present in 18%
to 20% in males and 5% in females [101].
There is, however, renewed interest in this topic since
there have been a number of case series reported from
Europe of delayed haemolytic anaemia following treatment
of severe malaria with injectable artesunate [102,103]. All
cases were successfully treated with transfusions. The syn-
drome, now labeled as Post-Artesunate Non-infectious
Delayed Haemolysis and Anaemia (PANDHA) or PADH
for short, is reported to occur in up to 25% of artesunate-
treated non-immune adults, typically two weeks after the
treatment course. An expert group review panel reviewed
world literature and found that PADH was not specific to
a particular preparation or manufacturer [104]. Further in-
sights into its pathogenesis have now been established
as the delayed clearance (through haemolysis) of once-
infected red cells. These ‘pitted’ erythrocytes had been
previously spared by artesunate (with quinine treatment
they would be removed from the circulation), since the
artemisinins induce splenic removal of parasites leaving
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Why some patients are susceptible to PADH remains
unknown. Data from malaria endemic areas on the oc-
currence of this condition are lacking.
Increased risk of bacterial co-infection
Bacteraemia is an important complication of severe mal-
aria in African children but is often under recognised,
largely a result of limited and poorly maintained micro-
biology services across sSA. Nevertheless, data have
slowly emerged, mainly from hospitals linked to research
programmes, indicating that there may be a biological
link between malaria and susceptibility to invasive bac-
terial infection (IBI). A study in Teule, Tanzania, re-
ported that up to a third of paediatric severe malaria
deaths were attributed to bacteraemia [106]. Another
large epidemiological study conducted in Kilifi, Kenya,
showed that more than 50% of all cases of bacteraemia
occurred in the presence of malaria [107]. A systematic
review compiling data from epidemiological studies and
clinical studies of paediatric hospital admissions of P.
falciparum malaria (describing IBI) across sSA examined
the evidence supporting a biological or epidemiological
relationship [108]. In the meta- analysis of ten studies
which included data from 15 centers in 11 sSA countries
involving 7,208 children with severe malaria, reported
over the period 1992 to 2010, found a mean prevalence
of IBI co-infection of 6.4% (95% CI 5.81 to 6.98%). Bacter-
ial co-infection resulted in higher case fatalities compared
to children with severe malaria alone 81/336 (24.1%) ver-
sus 585/5,760 (10.2%). The major pathogens associated
with IBI were non-typhoidal salmonellae (NTS), Escheri-
chia coli and other enteric gram-negative organisms.
There was also some evidence indicating greater risk of
NTS IBI in children with malarial anemia [108].
In order to reduce IBI-associated malaria mortality,
whilst minimising the risks of excess antibiotic prescrib-
ing, further research is needed to establish children at
greatest risk of bacteraemia, to inform a policy for targeted
antibiotic therapy. For example, Nadjm and colleagues
proposed simple clinical criteria [106] which identified
85% of malarial cases with culture-proven bacteraemia.
The criteria included an axillary temperature >38°C
or <36°C with parasitological evidence of current or re-
cent P. falciparum malaria infection plus one or more
of: prostration, respiratory distress (chest indrawing or
deep breathing), severe anaemia (Hb <5 g/dL), or HIV
infection. A pathogen was isolated from aerobic blood
cultures in approximately 20% of children (1-week to
12-years old) meeting these criteria. The ‘Teule criteria'
are yet to be tested in prospective intervention trials,
which could help with future policy of directed (where
microbiological services are not available) or short-course
empiric therapy with early termination guided by cultureresults to prevent development of resistance, which is
commonly practiced in high-income countries [109].
Treatment of severe malaria
Quinine has been the mainstay of treatment for African
children with severe malaria for decades; it remains ef-
fective and little drug resistance has been reported from
the continent. The arrival of the artemesinin compounds
led to a series of small clinical trials to test their safety
and efficacy. The first comparative clinical trials investi-
gated artemether (derivative of dihydroartemisinin, the
active antimalarial agent), which because of its poor
water solubility can only be injected by the intramuscu-
lar route. In clinical trials it proved to be safe but when
the data on efficacy were collated in a meta-analysis (in-
cluding 1,919 randomised patients) it did not lead to an
improved overall survival, specifically in African chil-
dren. This was followed by trials investigating another
artemisinin formulation, artesunate, which in contrast to
parenteral artemether, is water-soluble and can be given
intravenously and is instantly bioavailable [110]. Even
intramuscular artesunate is absorbed reliably and rap-
idly, with peak concentrations occurring within one hour
[111]. The SEAQUAMAT trial, conducted in South East
Asia (including 202 children) was stopped early after en-
rolment of 1,461 patients owing to a substantial benefit
for patients receiving artesunate [33]. Mortality in arte-
sunate recipients was 15% (107 of 730) compared with
22% (164 of 731) in quinine recipients; a relative reduc-
tion of 34.7% (95% CI 18.5 to 47.6%; P = 0.0002).
A further trial in African children was justified since
expert review at that time considered that the issue of
parasite drug resistance to quinine was not an issue (as
it was in South East Asia), that quinine remained the
optimal antimalarial and owing to the rapid tempo of
severe disease in African children with severe malaria
compared with adults in South East Asia there were
questions about the generalisabilty of the SEAQUAMAT
trial. In severe malaria in children most deaths occur
within the first 24 hours whereas survival benefit for many
patients in the SEAQUAMAT trial occurred after this
time point. These issues highlight the importance of equi-
poise as a strong scientific justification and a prerequisite
to conduct further clinical trials with meaningful clinically
relevant endpoints (that is, disability-free survival). The
AQUAMAT trial enrolled children at the point of hospital
admission. The criteria for enrolment were broad and
pragmatic with a view to future generalisability of the trial
results, principally if the clinician considered the child
required parenteral antimalarial medication they were
eligible for inclusion in the trial. Diagnosis was rein-
forced by quality controlled laboratory evidence of P.
falciparum malaria infection. The primary endpoint was
in-hospital mortality. By intention to treat, 297 children
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(8.5%) children who received artesunate. Overall, this
translated to a relative reduction in mortality of 22.5%
(95% CI 8.1 to 36.9) in children in the artesunate arm
(P = 0.002) [30], with no difference in outcome whether
the drugs were administered intravenously or intramus-
cularly. In the analysis of secondary endpoints there
were no differences in outcome across any of the major
clinical spectra defining severe malaria. The develop-
ment of coma and/or convulsions was more common
during hospital admission in the quinine arm (P = 0.02);
but there were no other differences between the arms
in number of other complications, additional treatments
prescribed, time to recovery or numbers with neurological
sequelae – which included 61 persistent mild, moderate
or severe such sequelae among survivors [30]. The trial
led to a major guideline change for anti-malarial treatment
of paediatric severe malaria, which now recommends a
preference for parenteral artesunate over quinine [21].
Adjunctive therapies in severe malaria
The outcome of severe malaria is largely determined by
the complications and number of vital organ dysfunction
and quality of care available. For most African children
this will not include an admission to an intensive care or
high-dependency care unit, instead management will be
more usually on a busy paediatric ward. It is important
to emphasize that the most important factor for man-
agement is the implementation of specific antimalarial
drug treatment and that this is given as early as possible
to reduce the risk of adverse outcome. As is the case in
management of severe sepsis, supportive therapies aimed
at correcting deranged physiology are also fundamental
to improving outcome; however, of the adjunctive agents
tested in clinical trials in both adults and children all
have failed to show benefit, with the exception of renal
replacement therapy in adults [112]. With respect to the
high risk group of cerebral malaria, of the 33 clinical tri-
als summarised in Table 2 investigating a range of spe-
cific or supportive therapies, 15 have been targeted to
the sub-group with cerebral malaria and most have shown
harm in those receiving the interventional therapy. These
will be reviewed, initially in chronological order, but are
largely clustered within a treatment-specific paradigm.
In general, many of these trials were single-centre
phase I or II studies with low sample sizes, often con-
strained by funding and slow or truncated trial recruit-
ment. A number of trials were terminated early due to
political instability, meeting pre-defined safety stopping
rule or due to evidence of adverse outcome in the inter-
ventional arm. Many trials had primary endpoints tar-
geting clinical surrogates for prognosis (for example,
correction of acidosis or cytokine or parasite clearance)
and so, as is usual in Phase II trials were not powered toinform meaningful endpoints such as mortality, but are
important steps in the justification for further testing in
larger trials. Methodological issues were noted in some
trials, for example, in some the primary endpoint was
not pre-specified, methods of randomisation were not
reported and some trials appeared to recruit patient po-
pulations with substantially lower overall lower mortal-
ity than would be expected, thus reducing the external
validity of the results. How we interpret these trials is
possibly helped by one overarching emerging theme:
that most did not result in a positive outcome for any of
the patient-centred endpoints in the interventional arms
(that is, those that are clinically relevant). Ordinarily,
the early stopping of trials, especially when interim ana-
lysis suggests large treatment effects, has been criticised
as, more often than not, interim results on small num-
bers tend to overestimate treatment effects [113] which
are often not replicated in larger multi-centre studies.
Some therapies may have been disregarded for the same
reason in severe malaria; however, it would be difficult
to warrant further exploration of a therapeutic interven-
tion in which a trial had been stopped by an external
committee reviewing safety for excess harm rather than
for futility.
Steriods: dexamethasone
In order to reduce or prevent cerebral oedema, two sep-
arate trials investigated whether the addition of dexa-
methasone improved the outcome of cerebral malaria in
adults and children [114,115]. The trial in Thai adults
showed that dexamethasone-treated patients had a more
prolonged period of coma (mean 63.2 hours versus
47.4 hours in the placebo arm). Disturbingly, its use led
to an increased risk of pneumonia and/or gastrointes-
tinal bleeding in 26/50 compared to 11/50 in the placebo
arm [114]. The second trial, conducted in Indonesian
children and adults with cerebral malaria, also showed
that dexamethasone led to an increased risk of gastro-
intestinal bleeding with no apparent benefit [115]. A
Cochrane review that pooled the data from these two
trials (N = 143 participants) found no difference in mor-
tality (relative risk 0.89; 95% CI 0.48 to 1.68; 143 partici-
pants, increased risk of GI bleeding in both trials 7/71
(10%) in the intervention-arm compared to 0/72 (0%) in
control, a relative risk of 8.17 (1.05, 63.57). The review
found no overall increased risk in invasive bacterial in-
fection [116] but highlighted that a major limitation was
that neither had trial follow up beyond discharge from
hospital, so that the effects of corticosteroids on residual
neurological deficits, therefore, could not be assessed.
The review concluded there was no evidence to support
the use of dexamethasone in cerebral malaria, although
numbers involved were small and the assessment of
complications in both trials was incomplete.
Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children
Study Country Age group Inclusion criteria/
sample size
Interventions and dosage Clinical outcome or
measures
Result Comment
Steroids
Warrell et al. [114] Thailand 6 to 60 years Cerebral malaria
N = 100
RCT (allocation in pairs)
Dexamethasone (DMO) over
48 hours adults 0.5 mg/kg
initially then 7 doses of 10 mg
each; children 0.6 mg/kg
initially then 7 doses (total
dose 2 mg/kg) (50) vs placebo
(50) plus quinine
10 Death in hospital Deaths in DMO 8/50 (16%)
vs 9/50 (18%) placebo
No benefit. Prolonged
coma among the survivors:
the interval between the
start of treatment and the
full recovery of
consciousness was 63.2
+/-5.9 hours (mean +/S.E.
M.) in the dexamethasone
group, as compared with
47.4 +/-3.2 hours in the
placebo group (P = 0.02).
Complications, including
pneumonia and
gastrointestinal bleeding,
occurred in 26 patients
given dexamethasone and
11 given placebo
(P = 0.004)
20 Neurological sequelae at
discharge; time to become
rousable and to regain full
consciousness;
complications
Hoffman et al. [115] Indonesia 1.5 to 42 years Cerebral malaria
N = 43
Dexamethasone (DMO) (3 mg
doses 8 hourly for 48 hours) vs
placebo plus quinine
10 Death in hospital Death DMO: 6/21 (28%) vs
placebo 7/22 (31.8%) mean
time to coma resolution
DMO 83.4 hours (SD = 49.3)
vs 80.0 hours (SD 59.4) in
placebo
No benefit from addition of
DMO in cerebral malaria
20 Time to become
rousable; time to regain
consciousness; duration of
fever; complications
Coma or hyperparasitaemia
(>5%) and hypoglycaemia
at any time during
hospitalisation were
significantly correlated with
a fatal outcome, but were
not improved by using
dexamethasone. DMO arm
increased risk of GI
bleeding.
Anti-inflamatory: Pentoxifyllin (Pt) and asprin
Di Perri et al. [117] Burundi <14 years Cerebral malaria
N = 100
RCT Only coma resolution
pre-specified (sample size
calculation)
Deaths in Pt 0/26 vs 5/30
(17%) control
Stopped after enrolling 56
patients due to civil conflictPentoxifyllin (Pt) (10 mg/kg/
day in saline as a continuous
infusion over 72 hours) vs
control plus quinine
Coma resolution 6 hours
vs 4 hours (no SD given).
Neurological sequelae Pt
arm 2/26 (7.7) vs 2/25 (8%)
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Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children (Continued)
Looareesuwan,
et al. [118]
Bangkok
Hospital for
Tropical
Diseases
>16 years old Severe malaria
N = 45 (15 per arm)
Three arm placebo controlled
trial
Outcomes included
mortality, resolution of
coma, renal failure,
respiration failure, fever and
parasite clearance time
No deaths in any group; no
difference in coma
resolution, duration of
intubation, haemodialysis
treatments and use of
transfusion. Mean parasite
clearance times were 59.2,
60.8, and 57.6 hours in
Groups I, II, and III
No significant differences
among the three treatment
groups were found for any
of the outcomes.
Pentoxifylline as an
adjunctive treatment
produced no clinically
evident benefit.
I/ high dose of Pt
(1.67 mg/ kg/hr)
II/ Low dose Pt
(0.83 mg/kg/hr).
III/ placebo (0.9% NaCl, 1 ml/
kg/hr) over 72 hours
Hemmer et al. [119] Hamburg,
Germany
Adults Falciparum malaria
N = 100 projected
Placebo controlled trial
Pentoxyfylin (20 mg/kg/ daily
infused over 24 hours) vs
placebo (saline infusion). One
patient in Pt arm did not
receive the drug. Only six
patients in each group had
severe disease (received
quinine)
Only endpoint specified
was TNFα
No difference in TNFα in Pt
arm vs placebo. Subgroup
patients with mild disease
TNFα levels on day 4 vs
placebo (P <0.01)
Trial stopped early for
futility and concern that
there were excess adverse
events in the Pt arm.
52 randomised (27 Pt
vs 24 placebo)
Non severe patients
mefloquine (Pt 20 mg/kg x 3
doses taken 6 hours apart) or
halofantrine (20 mg/kg x 3
doses 6 hours apart)
No effect of time to fever
defervescence, parasite
clearance or hospital stay
Pt arm AEs included nausea
(8), vomiting (7), general
uneasiness (2), palpitations
(1), and discomfort with
intravenous cannulae
plastic needle (1) vs 3 in
the placebo group:
discomfort with
intravenous cannulae
plastic needle (3) and
general uneasiness (1).
(P <0.05)
Das et al. [120] Orissa, India Adults Cerebral malaria
N = 52 (30 control
vs 22 Pt)
RCT Not pre-specified Coma resolution time
better in Pt than control
21.6 ± 13.9 vs 63.5 ±
19.7 hours (P <0.001)
Pt arm TNFα levels
decreased on day 3 (TNF.
47.92 pg/ml SD . ± 27.9;
P = 0.0029), compared to
admission values but in
control there was a rise in
TNFα levels (TNF . 589 pg/
ml SD . ± 602.3; P >0.05).
Group 1 quinine only, Group
2: Pt support (10 mg/kg/day)
for the initial 3 days plus iv
quinine Method of allocation
not specified Mortality Pt 10% (n = 2) vs
27% (8) in control (P >0.05)
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Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children (Continued)
Lell et al. [121] Kilifi, Kenya 9 months to
8 years
Cerebral malaria
Estimated N = 20/15
Step-dose escalation 10 Mortality and 3 months
neurological sequelae (NS),
SAE
Recruited 10 Pt and 5
control
Stopped early for safety
concerns, mortality rate was
unexpectedly high in the
PTX group but sample size
too small for definitive
conclusions.
10 mg/kg up to 40 ml/kg
Pentoxifyllin vs control
20 coma resolution; fever
and parasite clearance
10 Death Pt 4 (40%) vs
control: 1 (10%) 2 other
SAE in Pt arm 72 hour
neurological impairment
Pt = 1(17%) vs 2 (50%) NS
at 3 months Pt = 0 (0%) vs
1 (25%)
20 Coma resolution time
(hours) Pt = 8 (4 to 36) vs 8
(4 to 12)
Hemmer et al.
(1997) [119]
Hamburg,
Germany
>14 years Severe and non
severe malaria (25
had altered or
abnormal renal, liver
or coagulation tests)
N = 97
Prospective RCT Not pre-specified Fever defervescence (days) There were no significant
differences in any of the
parameters (parasite
clearance, defervescence
time, or length of hospital
stay) between patients
receiving heparin, ASA, or
the controls.
3 arms: i/33 low-dose heparin
(70 units/kg tds for 5 days sub-
cut, ii/31 iv aspirin (500 mg on
day 0, 2 and 4) iv, iii/ 33
control.
5 (range 2 to 9) heparin vs
4 (2 to 9) aspirin vs 3 (2 to
6) control
Length of hospital stay 9
(4 to 54) vs 8 (4 to 27) vs 8
(4 to 31) days respectively
Monoclonal antibodies, immunoglobulin and anti-sequestration therapies
van Hensbroek
et al. [122]
Banjul, The
Gambia
1 to 9 years Cerebral malaria
N = 610 (of 624: 14
either died before
or unable to receive
medication)
RCT Placebo controlled (in a
2 X 2 Factorial trial Monoclonal
Ab (Mab: against TNFα) in
human serum albumin (0.1%)
vs placebo. A single i.v.
infusion over 15-mins (other
randomization: im artemether
vs quinine)
10 mortality in hospital and
residual neurologic
sequelae (NS) (6 months).
10 Death Mab (60/302;
19.9%) vs (64/308; 20.8%)
P = 0.9, NS at 6 month 6.8%
(15/221) vs 2.2 (5/225)
P = 0.04
Faster fever clearance on
Mab arm. After adjustment
for severity features and
antimalarial strategy there
was no significant survival
benefit in children treated
with Mab but significantly
increased NS rate at
6 month in survivors (15/
221 (6.8%) in the Mab arm
compared with 5/225
(2.2%) 3.35 (1.08 to 10.4)
P = 0.02
20 parasite and fever
clearance rates, coma
recovery time, neurologic
sequelae (NS) at discharge
and 1 month
20 NS at discharge 24.4%
(59/242) and 22.1% (54/
244); P = 0 .6 and NS at
1 month 11% (25/228) vs
6.4% (15/234) P = 0.1
Taylor et al. [123] Blantyre,
Malawi
1 to 12 years Cerebral malaria (BCS
< = 1) n = 31
Placebo controlled trial i.v.
immune globulin (IVIG)
(pooled from local blood
donations) during the first
3 hours treatment plus quinine
10 Composite of mortality
or neurological sequelae
16 received IVIG; 15
placebo
Trial was stopped (based
on preplanned stopping
rules) – no benefit of IVIG.
Placebo vs IVIG: Odds ratio
death or sequelae = 0.24
(95% CI 0 to 05, 1 to 26
that is, odds of failing on
placebo were about 1/4 of
the odds of these events
on IVIG
20 Hours to regain full
consciousness; Fever
resolution; parasite
clearance
Died or sequelae
IVIG = 5 + 5 = 10/16 (62.5%)
Placebo 1 + 2 = 3/15 (20%)
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Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children (Continued)
Looareesuwan, et al.
[118]
Bangkok,
Thailand
>14 years Severe malaria
N = 23 (12 vs 11)
Placebo controlled trial
Polyclonal anti-TNF Fab
(n = 12) received 250, 500, or
1,000 units/kg (4 pt each
dose). 5 received 2,000 units/
kg. Controls (n = 11) saline
100 ml. Treatment allocation
not stated.
Clinical endpoints included
duration of coma (CM only)
development of severe
complications. Mechanistic
and PK data generated
Coma recovery only
reported in 5 patients
(3 Fab vs 2 control) Adverse
effects: weakness was
present longer in controls
5 days (range 3 to 21) vs
4.0 (2 to 14) in Fab arms
Too few patients in the trial
with CM (n = 7) to assess
efficacy on coma recovery.
Only one patient died
(control) arm.
Maude et al. [126] Chittagong,
Bangladesh
>or = 16 years P. falciparum (>2%)
plus modified WHO
severe malaria criteria
N = 60
Phase II Controlled RCT
Levamisole 150 mg po or ng
stat dose immediately vs
control plus artesunate
Composite: Clinical Death
or coma recovery Parasite
clearance and lactate
Pharmacodynamics
Microvascular flow
Death 5/29 (17%)
Levamisole vs 9/27 (33%)
P = 0.22
Levamisole inhibits
cytoadherence in vitro and
reduces sequestration of
late-stage parasites.
No differences in
proportions of trophozoites,
measures of parasite
clearance in blood over
30 hours or effects
sequestration
Speculated whether rapid
clearance of malaria
parasites by artesunate may
obscure beneficial effects of
levamisole.
Seizure prophylaxis
White et al. [127] Thailand Children
>6 years and
adults
Cerebral malaria
N = 46
Double blind RCT: 3.5 mg/kg
single dose given IM
phenobarbitone (Pb) n = 24
Control (n. saline) n = 24
10 Seizure prevention 10 Convulsions in Pb arm
3/24 (12-5%), vs 13/24
(54%) placebo (P = 0-006).
Seizures prevention
superior
20 Death 20 Deaths 8 (33%) in Pb
arm 5 (20.8) placebo arm
(P = 0.5)
Small numbers in trial not
able to assess effect on
mortality.
Kochar et al. [130] Rajasthan,
India
Adults age 14
to 74 years
Cerebral malaria
N = 185
Randomly assigned: Not specified 3/102 (3%) developed
seizures after admission in Pb
arm vs 19/83 (22.9%) control
Reported as a
correspondence not
formally reported as a peer
reviewed manuscript.
10 mg/kg im one dose of
phenobabitone (Pb) (n = 102)
Control (n = 83) Deaths Pb: 29/102 (28.4%
vs control 33/83 (39.8%)Pb
Crawley et al. [128] Kilifi, Kenya Children
9 months to
13 years
Cerebral malaria
N = 340
Placebo controlled trial 10 Seizure prevention 10 Seizure frequency lower
in the Pb arm vs placebo
group (18 (11%) vs 46
(27%) children had 3 or
more seizures OR: 0.32
(95% CI 0.18 to 0.58)
Frequency of respiratory
arrest was higher in the
phenobarbital arm vs
placebo arm
170 Pb arm/
170 placebo arm
A single intramuscular dose of
phenobarbital (Pb) (20 mg/kg)
or identical placebo plus
quinine
20 Death 20 Mortality higher in
phenobarbitone arm (30
(18%) vs 14 (8%) deaths; OR
2.39 (1.28–4.64)).
Mortality substantially
increased in children who
received phenobarbital plus
three or more doses of
diazepam (OR 31.7 (1.2 to
814))
Not recommended in CM.
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Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children (Continued)
Gwer et al. [129] two centres
Kilifi and
Kisumu
hospitals,
Kenya
Children
9 months to
13 years
Blantyre Coma Score
< =2 (included CM
and non-traumatic
encephalopathy)
Placebo controlled trial a
single dose of Fosphenytoin or
placebo plus quinine (N = 173)
10 Seizure prevention and
neurologic sequelae
(3 months)
CM sub group (n = 110),
Seizure prevalence
fosphenytoin (n = 20/54;
37%) vs placebo (n = 21/56;
38%) (P = 0.233)
Neurological sequelae 5
children (11%) vs 9 (19%) in
the placebo arm (P = 0.98)
Stopped early (low
enrolment/futility). No
difference in clinical or EEG
evidence of seizures
(P= .980); gross neurological
sequelae (P= .283).
85 received Fosphenytion
Deaths not specifically
reported for CM subgroup
but overall fosphenytoin 18
(21%) vs placebo 15 (17%)
(P = .489)
88 placebo
20 Death
Cerebral oedema prevention: osmotherapies
Mohanty et al. [133] India Adults CM with evidence of
brain swelling on
admission CT scan
Controlled trial 10 Death 10 Death mannitol 9/30
(30%) vs 4/31 (13%) control
Mannitol led to increased
mortality (P = .11) and
prolonged coma duration
(P = .02)1.5 g/kg mannitol followed by
0.5 g/kg every 8 hours vs
control (no mannitol)
20 Time to regain
consciousness
Time to coma recovery
90 hours (IQR 22 to 380) vs
32 hours (IQR 5 to
168 hours)
Namutangula et al.
(2007) [132]
Kampala,
Uganda
Children 6 to
60 months
Cerebral malaria
N = 156/156
Placebo controlled trial single
dose mannitol (1 g/kg) vs
placebo plus quinine
10 Time to regain
consciousness
10 Time to conscious was
18.9 hours (10 to 38)
(mannitol) v 20.5 hours
(14 to 53) (control)
No difference in any
endpoint; no adverse
events.
20 Death 20 Death mannitol 9/75
(12%) vs control 13/76
(16%)
Iron chelation therapy
Gordeuk et al. [135] Zambia Children
<6 years
Cerebral malaria;
unrousable coma
N = 78
Placebo controlled
Desferrioxamine (DFO)
100 mg/kg/day intravenously
for 72 hours vs placebo
10 Mortality Mortality DFO 7/42 (16.7%)
vs placebo 9/41 (22%).
Coma recovery DFO:
20.2 hours (N = 41) placebo:
43.1 hours (N = 42) P = 0.38
Relative risk of mortality in
DFO arm 0.76 (95% CI 0.31,
1.85)
20 Time to recovery of full
consciousness; parasite and
fever clearance times
Coma recovery 1.3 times
(95% CI 0.7 to 2.3) faster in
DFO group than in placebo
Thuma et al. [136] Zambia; two
centres
Children
<6 years
Cerebral malaria;
unrousable coma;
clear CSF
Placebo controlled
Desferrioxamine (DFO)
100 mg/kg/day intravenously
for 72 hours vs placebo
N = 352
10 Mortality Trial stopped early by
DSMB after mortality 32/
175 (18.1%) DFO arm vs
19/177 (10.7) placebo arm
Increased risk of death in
DFO arm (RR 1.70, 95% CI
1.00 to 2.89)
20 Coma recovery (time to
Blantyre Coma Scale: 5);
parasite and fever clearance
times; parasite clearance
day 3 Coma recovery time 1.2
times faster in DFO group
vs placebo (P = 0.21) DFO:
18.1 hours (N = 143)
placebo: 19.0 hours
(N = 158) 95% CI 0.97 to 1.6
Persistent seizures >3 lower
in DFO 93/168 vs 115/166
(RR 0.8; 0.67 to 0.95) but
recurrent hypoglycaemia
higher 43/172 vs 29/172
(RR 1.48 (0.97 to 2.26))
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Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children (Continued)
Mohanty et al. [137] Mumbai India 13 to 84 years Severe malaria
N = 45
Blinded placebo controlled
trial 1. Deferiprone (75 mg/kg/
day divided in 2 daily doses)
2. Placebo capsules plus
antimalarials (10 days)
10 Mortality No deaths
20 Coma recovery; parasite
clearance time
Coma recovery time better
in DFO arm 29 hours
(SD10) vs 56 (14).
Acidosis correction
N-acetylcysteine (NAC)
Watt et al. [139] Bangkok,
Thailand
Males 18 to
50 years
Severe malaria
N = 30 (15 in
each arm)
Phase II placebo controlled
trial 1/ NAC dose 150 mg/kg
over 15 mins, followed by
50 mg/kg over 4 hours, then
100 mg/kg over 16 hours (in
5% dextrose infusion): vs 5%
dextrose (placebo) plus
quinine
Lactate acidosis resolution NAC lactate resolution at
24 hours 10/15 better than
placebo (3/15) P = 0.011
Small phase II trial
Median coma resolution
faster NAC 24 hours (6 to
60) vs 36 hours (18 to 120)
P = 0.19.
Overall low mortality and
few received renal dialysis.
Treeprasertsuk et al.
[140]
Thailand 13 years or
older
WHO (2000)
definition of severe
malaria Patient had
to agree to stay
in-hospital until Day
28 (N = 108; 54 NAC
regimens; 54
placebo)
Placebo controlled trial of 3
NAC dosage regimens plus
artesunate
Not specified; method of
randomization not specified
either
54 received NAC Gp 1
(n = 31), Gp 2 (n = 5)b and
18 in Gp 3 (N = 18) Gp 4
(n = 54)
bGroup 2 oral
administration not tolerated
as given too early and in a
large amount of liquid
volume)
Group (Gp 1) iv: 140 mg/kg
loading dose then 70 mg/kg
4 hourly x 18 doses; Gp 2) a
single iv loading dose
followed by oral NAC (see
doses Gp 1) Gp 3) iv: loading
dose (140 mg/kg) then
70 mg/kg 4hourly for 24 hours
then oral NAC Gp 4) placebo
Deaths-only 2 in Group 1.
Fever clearance and
parasite clearance times –
no major differences
Data on fever and parasite
clearance time were
summarised in table by
arm but not compared
statistically.Withdrawal rate
Inconclusive study;
incomplete reporting.
Gp 1 (4; 13%), Gp 2
(3; 60%), Gp 4 (10; 18.5%)
Charunwatthana
et al. [141]
Mae Sot
General
Hospital,
Thailand and
Chittagong,
Bangladesh
>16 years Modified WHO
severe malaria
(N = 108: 56 NAC,52
placebo)
Placebo controlled RCT NAC:
150 mg/kg over 15 mins,
followed by 50 mg/kg over
4 hours, then 100 mg/kg over
16 hours (in 5% dextrose) vs
saline/5% dextrose (placebo)
plus iv artesunate
10 Lactate clearance time,
coma recovery time and
parasite clearance time.
Others: fever clearance
time, mortality, red cell
deformability
No difference in lactate
clearance (adjusted for
admission parasitaemia and
bilirubin) (hazard ratio 0.98
(0.60, 1.62) or median coma
recovery time (72 hours vs
96 hours) adjusted for
censored deaths
No difference in case
fatality rate: 21 (38%) in the
NAC group vs 17 (33%) in
the placebo group.
Treatment with
Nacetylcysteine had no
effect on outcome in
patients with severe
falciparum malaria
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Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children (Continued)
L-arginine
Yeo et al. [142] Timika, Papua,
Indonesia
18 to 60 years Modified WHO severe
malaria criteria N = 8
Placebo controlled RCT 12 g
L-arginine hydrochloride vs
saline over 8 hours plus iv
astersunate
Measures of
haemodynamic function,
endothelial function and
nitric oxide bioavailability,
lactate clearance
No deaths; no adverse
events; arginine did not
improve lactate clearance
nor endothelial nitric oxide
(NO) bioavailability
L-arginine was given to an
increase endothelial nitric
oxide: since low NO and
hypo-arginaemia associated
with severe malaria. Study
stopped early due to local
political instability.
(6 L-‐arginine; 2
placebo)
L-Arginine was found to be
safe but no benefit shown
in small number studied.
Further studies may require
higher dosing.
Shock management: resuscitation fluids and vasopressors
Day et al. [68] Ho Chi Minh
City, Viet Nam
Adults 23 patients
critically-ill with
severe sepsis
(n = 10) or severe
malaria (n = 13).
Open, randomised, crossover
study comparing increasing iv
adrenaline doses of 0.1 to
0.5 g/kg per min vs dopamine
2.5 to 10 g/kg per min.
Comparing adrenaline and
dopamine effect on
acid-base balance and
haemodynamics: incidence
of drug- associated
hyperlactataemia (rise
in plasma lactate of
>3 mmol/L)
9 received adrenaline first,
and 14 received dopamine.
Overall, 4 patients required
both dopamine and
adrenaline to normalise
SBP. The full dopamine
dose-profile protocol was
effected in 19 patients.
Development of lactic
acidosis curtailed the
adrenaline dose-profile at
some stage in 16 patients
(84%) P = 0.0002.
Infusion of inotropic doses
of adrenaline in severe
infections resulted in the
development of lactic
acidosis.
No significant differences
were found between sepsis
and malaria subgroups with
respect to disease effects or
responses to treatments.
Maitland et al. [60] Kenya Children
>6 months
Severe malaria plus
deep breathing and
base deficit >8
N = 53
Dose finding study 0.9% saline
(N = 20); 4.5% human albumin
solution (HAS (N = 32). Boluses
of 10 to 40 ml/kg given over
1st hour after admission
Aliquots of 10 ml/kg given
to achieve CVP 5 to 8 cm
and improvement in
haemodynamic indices.
Resolution of acidosis/base
deficit reduction at 8 hours
Mean central venous
pressure (SE) at admission
was 2.9 cm H2O (0.5 cm
H2O); in those with base
deficit >15 (445 had
hypotension); by 8 hours
mean CVP = 7.5 mm HG
and evidence of resolution
of shock and respiratory
distress.
Inadequate allocation
concealment and
inadequate sequence
generation.
No evidence of adverse
effects of fluid overload;
there were only 4 deaths
(case fatality 7.5%) and in
the survivors, there were no
apparent neurologic deficits
at discharge.
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Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children (Continued)
Maitland et al. [145] Kenya Children
>6 months
Severe malaria (Hb >
5 g/dl) plus deep
breathing and base
deficit >8 N = 150
RCT fluid resuscitation
(20 ml/kg = bolus) 1. 4.5%
albumin N = 61; 2. 0.9% saline
N = 56 3. Controlc N = 33.
10 Acidosis correction:
mean percentage reduction
in base excess admission to
8 hours.
10 no difference in the
resolution of acidosis
between the groups;
control only eligible if base
deficit >8 but <15:
20 Mortality; SAE of fluid
overload; neurological
sequelae (NS)
20 mortality lower in
albumin arm (N = 2 3.6%)
vs saline (N = 11, 18%).
Relative risk of mortality
saline vs albumin 5.5 (95%
CI 1.2 to 24.8; P = .013)
Subgroup analysis
Base deficit >15: Deaths:
albumin 2/23 (9%) vs saline
8/26 (33%)
NS: albumin 3/21 (14%) vs
saline 1/18; (6%)
Base deficit 8 to 15: Deaths:
Albumin 0/33, Saline 3/35
(9%) vs Control 2/33 (6%)
Maitland et al. [150] Kenya Children
>6 months
Severe malarial
anaemia (Hb < = 5 g/
dl) plus deep
breathing and base
deficit >8; N = 61
Pre-transfusion bolus
management RCT
10 Acidosis correction
(as above)
10 no difference: albumin
group 44% (95% CI 32 to
57%); saline group 36% (16
to 57%); control group 42%
(19 to 66%) P = 0.7
Tolerability of protocol
control 4 (22%) developed
decompensated shock:
albumin 4 (17%) required
emergency interventions;
two had salicylate toxicity
and 1 had sickle cell
anaemia. No need for
alternative treatments in
the saline group.
1. 4.5% albumin N = 23 20 Mortality; SAE of fluid
overload: pulmonary
oedema, neurological
events 20 Deaths albumin 4 (17%);
saline3 (15%); control3 (17%);
No adverse events
2. 0.9% saline N = 20
Neurological sequelae
3. control N = 18
Akech et al. [151] Kenya Children
>6 months
Severe malaria,
deep breathing
and base deficit >8
N = 88
RCT 20 ml/kg over the first
hour, repeat if shock
persists
10 Acidosis and shock
correction
10 No difference in the
resolution of shock or
acidosis
Per protocol analysis of
mortality albumin: 1/40
(2.5%) vs gelofusine 4/40
(10%), (P = 0.36)
1. 4.5% albumin (N = 44) 20 Mortality; SAE related to
fluid and neurological
sequelae
20 By ITT mortality albumin
(1/44; 2.3%) vs Gelofusine
(7/44; 16%) P = 0.06). No
pulmonary oedema/fluid
overload events. Fatal
neurological events more
common in gelatin arm.
2. Gelofusin (N = 44)
Akech et al. [152] Kenya Children
>6 months
Severe malaria
(Hb > 5 g/dl) plus
deep breathing
and base deficit >8
N = 79
RCT 20 ml/kg over the first
hour, repeat x1 if shock
persists
10 resolution of shock over
8 hours.
10 no difference in 8 hour
shock resolution (D70:
23/37 (62%) vs HES: 25/39
(64%), respectively (P = .99).
Fluid boluses with either
Dextran or 6% HES lead
shock and acidosis
resolution without
eividence of adverse
outcome. Specifically, there
was no evidence of a renal
impairment with HES over
24 hrs of observation, its use
was associated with falling
creatinine levels and good
urine output
1. Dextran 70 (N = 39)
20 resolution of acidosis,
in-hospital mortality,
SAEs (allergic reaction,
pulmonary oedema, and
neurologic sequelae)
20 Acidosis and respiratory
distress resolved better in
HES: 3/39 (8%) remained
acidotic at 8 hours vs D70
10/37 (27%) (P = .05). 4
deaths (5%): two per arm.
No SAEs
2. 6% hydroxyethyl starch
(N = 40)
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Table 2 Randomised clinical trials of adjunctive therapies in severe malaria in adults and children (Continued)
Maitland et al. [89] Multi- centre
6 sites East
Africa
Children Critically-ill with
severe sepsis
(N = 1330) or severe
malaria (N = 1793)
plus shock N = 3121
FEAST trial: an open RCT
comparing: 1) 5% albumin
bolus g; 2) 0.9% saline bolus
(saline- bolus group) 20 to
40 ml/kg over one hour;
3) no bolus (control)
10 48-hour mortality; 10 48 hour mortality DMC stopped trial early
(after enrollment of 3141 of
projected 3600)
2 months to
12 years
Plus iv antibiotics and/or
quinine
20 pulmonary oedema,
increased intracranial
pressure, mortality or
neurologic sequelae at
4 weeks
Sepsis: Bolus 108/884
(12.2%) vs 38/446 (8.5%) RR
1.43 (1.01 to 2.04).
Neurologic sequelae
occurred in 2.2%, 1.9%, and
2.0%, respectively groups 1,
2 and 3 (P = 0.92),
Pulmonary oedema or
increased intracranial
pressure occurred in 2.6%,
2.2%, and 1.7% (P = 0.17),
respectively.
Malaria: 110/1202 (9.2%) vs
control 34/591 (5.7%) RR
1.59 (1.10 to 2.31). 20:
28 days mortality 12.2%,
12%, and 8.7% respectively
(P = 0.004)
Transfusion
Bojang et al. [159] Banjul, The
Gambia
6 months to
9 years
Severe malarial
anaemia N = 114 (PCV
<15%) Exclusion:
immediate transfusion
or recent iron
treatment
Allocated ‘at random’ to
transfusion (15 ml/kg whole
blood N = 58) or iron
supplementation for month
N = 56 (infants = 2.5 mL tds;
<20 kg = 5 mL or if > 20 kg =
7.5 mL) 3 times a day plus oral
antimalarials
Not specified Day 7 mean PCV was
significantly less in children
who received iron than
transfused group (P = 0.001)
Day 28: iron treatment arm
had a significantly higher
mean PCV than transfused
arm
Day 90 not reported as at
Day 28, children were
allocated randomly to
receive weekly
chemoprophylaxis with
Maloprim (pyrimethamine
and dapsone) or placebo
Clinical reviews (plus
malaria slide and
haematocrit) on days 7,
28 and 90 after admission.
Olupot Olupot
et al. [160]
2 centres,
Mbale and
Soroti
hospitals,
Eastern
Uganda
2 months to
12 years
Severe anaemia
SA (Hb < 6 g/dl)
N = 160
Phase II RCT comparing whole
blood (30 ml /kg; Tx30:
N = 78) vs standard volume
(20 ml/kg; Tx20: N = 82)
10 correction of severe
anaemia (to haemoglobin
>6 g/dl) at 24 hours.
10 Tx30 70 (90%) corrected
SA vs Tx20 61 (74%) hazard
ratio = 1.54 (95% CI 1.1 to
2.2) P = 0.01
Higher volume of blood
than currently
recommended was safe
and resulted in an
accelerated haematological
recovery in Ugandan
children with SA.
(95 (59%)) had P
falciparum malaria (by
RDT or slide)
20 Re-transfusion; serious
adverse events; mortality
(48- hour and 28 days;
redevelopment of severe
anaemia
20 Global Hb increment
admission- Day 28 superior
in Tx30 (P <0.0001); SAE
and Death Tx30 = one non-
fatal allergic reaction and
one death (Tx30) vs 6
deaths in the Tx20 arm
(P = 0.12)
AEs, adverse events; CI, confidence interval; CSF, cerebrospinal fluid; CT, computed tomography; CM, cerebral malaria; CVP, central venous pressure; GI, gastrointestinal; Hb, haemoglobin; HES, hydroxyethyl starch;
IQR, interquartile range; ITT, intention to treat; N, number; RCT, randomised controlled trial; SAEs= serious adverse events; SBP, systolic blood pressure; SD, standard deviation; S.E.M, standard error of the mean; subcut,
subcutaneous; vs, versus.
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The pathogenesis of severe malaria involves several dif-
ferent processes, including enhanced production of the
cytokines including tumour necrosis factor (TNF), se-
questration of parasite red cells to the endothelium and
decreased erythrocyte deformability. Since pentoxfylline
(Pt) has beneficial effects on many of these processes, in
particular increasing red cell deformability (and thus
improving local tissue perfusion), it was postulated that
it might improve outcome in severe malaria. The next
phase of trials investigated the addition of Pt to standard
antimalarial therapies, primarily aimed at suppression of
TNFα production. In total, five trials investigated its use
in cerebral malaria, or all-cause severe malaria [117-121].
Two were conducted in African children (Burundi [117]
and Kenya [121]). Three trials were stopped early: one due
to civil conflict [117] and two due to safety concerns
[119,121]. The Burundi trial had enrolled 56 of a projected
100 children with cerebral malaria when it was stopped.
There were no deaths in the Pt arm (n = 26) compared to
5 of 30 (17%) in the control arm; 8% of both groups de-
veloped neurological sequelae [117]. Owing to the small
sample size the results were inconclusive. The second
paediatric study, a dose escalation study, conducted in
Kenyan children with cerebral malaria was stopped due
to safety concerns. A significantly higher mortality oc-
curred in the Pt arm 4/10 (40%) versus 1/5 (20%) in
controls [121]. A trial conducted in Thai adults (n = 45)
showed no significant differences in any of the arms
(which investigated low dose Pt, high dose Pt versus
control) for any of the outcome measures [118]. An-
other trial conducted in Indian adults involving 22 in
the Pt arm and 30 controls showed reductions in TNFα
(baseline to day 3) in the Pt arm compared to increases
in the control arm. Mortality was 25% in the control
arm and 10% in the Pt arm [120]. However, there were
methodological limitations in this trial since the me-
thod for allocation of study arms was not stipulated nor
were the study endpoints pre-specified. Owing to lack
of overall clinical benefit, and those that were favorable
largely related to secondary endpoints, and a suggestion
of increased adverse outcome, further exploration of
anti-TNF therapies have not been pursued.
Monoclonal antibodies, immunoglobulins and
anti-sequestration therapies
A controlled factorial trial of monoclonal antibodies
(Mab) against TNF-α in Gambian children (N = 610)
which also compared artemether and quinine, showed
faster fever clearance but no survival benefit in children
treated with Mab (19.9%) compared to controls (20.8%),
after adjustment for antimalarial strategy [122]. The trial
also demonstrated a significantly increased risk of long-
term (six months) neurological sequelae in survivors15/221 (6.8%) in Mab recipients compared with 5/225
(2.2%) in controls. The authors suggested that whilst
there was evidence that antibody acts to retain and pro-
long TNF within the circulation (leading to fever reduc-
tion) this may inadvertently increase its harmful effects
on the vascular endothelium and, in turn, aggravate neu-
rologic complications. A trial investigating pooled intra-
venous immunoglobulin (IVIG) from blood bank adult
donors and, thus, presumptively immune to malaria in
Malawian children with cerebral malaria was stopped
early after enrolling 31 children for futility (in accord-
ance to a pre-planned stopping rule) [123]. For those
receiving IVIG 10/16 (62.5%) died or developed neuro-
logical sequelae compared to 3/15 (20%) in the placebo
arm. A further placebo controlled trial conducted in
28 Thai adults >14 years old (enrolled using WHO
severe malaria criteria) investigated polyclonal anti-
TNF-α antibodies in addition to artesunate. Included in
the study were seven participants with cerebral malaria,
46% had hyperparasitemia (13 of 28) and 39% had circula-
tory shock (11 of 28) [124]. Compared to controls anti-
body treatment reduced IFN-g concentrations in a dose-
related manner and unbound TNF-α was undetectable
after Fab treatment, irrespective of dose. The composite
clinical endpoint, including duration of coma in cerebral
malaria and the development of other severe manifesta-
tions or complications, was hampered since it was only
possible to record coma recovery in five patients; hence,
the results were largely inconclusive.
A controlled Phase II trial investigating the use of the
oral anthelmintic drug levamisole hydrochloride (previ-
ously shown to inhibit cytoadherence in vitro and reduce
sequestration of late-stage parasites in uncomplicated P.
falciparum malaria [125]) included 56 Bangladeshi adults
with criteria for all-cause severe malaria [126]. Linked
pharmokinetic studies indicated absorption of levamisole
was reliable with a mean plasma level of 97% of expected
levels in healthy adults. However, there was little marked
effect upon parasite sequestration, lactate clearance (a
putative marker of tissue oxygenation and microcircula-
tory perfusion) or mortality. The authors suggested that
despite previous observations in uncomplicated malaria
treated with quinine, rapid parasite clearance with in-
travenous artesunate may have obscured any marginal
benefit of levamisole on parasite sequestration.
Seizure prophylaxis
Since convulsions are common in severe malaria, in par-
ticular the sub-group with cerebral malaria, and associated
with adverse outcomes including death and neurologi-
cal sequelae (in children), routine administration of anti-
epileptics to prevent the seizures was suggested. In a
double-blind controlled trial in Thailand involving both
children and adults with cerebral malaria, randomised to
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cebo, there was a lower seizure rate in the Pb group at
12.5% (3/24) compared to 54% (13/24) in the placebo
arm (P = 0.006) [127]. There was no effect on mortality,
eight (33%) versus five (21%), respectively. Based on this
small study the authors recommended that guidelines
should advocate that all patients with cerebral malaria
should receive a single intramuscular loading dose of Pb.
A large single centre paediatric placebo-controlled trial
(N = 340) conducted in Kenyan children with cerebral
malaria, designed to provide the evidence for this new rec-
ommendation, examined a single intramuscular dose of
Pb (20 mg/kg) versus placebo. As expected Pb recipients
had a lower rate of seizures (defined as three or more sei-
zures of any duration) than the placebo recipients (18
(11%) versus 46 (27%) odds ratio 0.32 (95% CI 0.18 to
0.58)) but the case fatality rate was more than double in
the Pb arm (30 (18%) compared to placebo 14 (8%) deaths,
relative risk 2.39 (95% CI 1.28 to 4.64)) [128]. The chief
mode of death in those receiving Pb was respiratory arrest.
Following this trial the guidelines changed and no longer
recommend Pb prophylaxis in cerebral malaria. A further
placebo controlled trial, conducted at the same centre in
Kenya, in non-traumatic encephalopathy (including a ce-
rebral malaria subgroup (N = 110)) investigated the use of
fosphenytoin (a drug often used for seizure prophylaxis in
neuro-trauma that has minimal cardiorespiratory side ef-
fects). It was terminated due to slow recruitment/futility.
At least one seizure (monitored clinically and by electro-
encephalogram) occurred in 33/83 (40%) in children re-
ceiving fosphenytoin versus 32/88 (36%) receiving placebo
(P = 0.733) [129]. In the cerebral malaria subgroup the
prevalence of seizures in the fosphenytoin arm was 20,
37% which was identical to the placebo arm 21, 38%.
Overall, 18 children treated with fosphenytoin (21%) died
compared with 15 in the placebo arm (17%) (P = 0.489). In
survivors rates of neurologic sequelae at three months
were the same (10%) in both arms [129]. A study from
India, reporting results from a clinical trial in adults as a
correspondence piece, gave only limited details of the clin-
ical trial methodology. The successful use of prophylactic
Pb reported in this trial is questionable since it was not re-
ported in full [130].
Osmotherapy: mannitol for treatment or prevention of
cerebral oedema
Leading up to these trials were two observational stud-
ies, one case series and one uncontrolled trial, investigat-
ing mannitol and other osmotic diuretics as adjuncts for
treating brain swelling (cerebral oedema) in African chil-
dren with cerebral malaria [39,131]. These early studies
suggested that mannitol may improve outcomes [39],
and case series of children receiving urea with dexametha-
sone was reported to have a dramatic improvement [131].A subsequent placebo-controlled trial, conducted in 156
Ugandan children with cerebral malaria, investigated a
single dose of 5 ml/kg of 20% (1 g/kg) of intravenous man-
nitol infused over 20 minutes in addition to intravenous
quinine. No important differences were found in the main
outcomes, including time to regain consciousness or death
[132]. Six children had postmortems of whom five had
signs of anoxia and cerebral oedema; the sixth child had
signs of acute tubular necrosis at autopsy. A controlled
trial examining the use of 1.5 g/kg mannitol followed by
0.5 g/kg every eight hours in Indian adults with death as
the primary endpoint found an increased mortality in
those receiving mannitol, 9/30 (30%), compared to 4/31
(13%) in the control (no mannitol) arm [133]. Mannitol
also prolonged coma resolution. Whilst there is good evi-
dence that brain swelling complicates both adult and
paediatric cerebral malaria, trials to date have shown no
benefit of osmotherapy or steroids (see earlier).
Iron chelation
The use of iron chelating agents was considered for ad-
junctive therapy in severe malaria. The positive hypo-
thesis suggested that by chelating free iron these drugs
would thus withhold iron which is required by malaria
parasites to mature and multiply and, thus, limit or in-
hibit parasite reproduction rate. A Cochrane review of
the data on the uses of iron chelation was conducted in
2007 [134]. Whilst seven trials involving 570 participants
met the inclusion criteria, four of these were excluded
as they included non-severe or asymptomatic malaria
or had methodological issues. In children with severe
malaria two controlled trials examined desferrioxamine
(DFO) [135,136] with cerebral malaria and one studied
deferiprone [137] in Indian adults (13 to 84 years) with
severe malaria.
The first study conducted in a Zambian hospital in-
volving 83 children with cerebral malaria indicated a
lower mortality in DFO recipients, 7/42 (16.7%), com-
pared to placebo, 9/41 (22%). Moreover, time to coma
recovery was faster in the DFO arm [135]. A second, lar-
ger paediatric trial conducted at two centres in Zambia
was stopped early on the recommendations of the data
monitoring committee for safety, as there were more
deaths in the DFO arm, 18.3% (32/175) compared to
10.7% (19/177) in the placebo group [136]. Overall, the
pooled estimate for both trials (435 participants) indi-
cated a non-significant increased risk of death in the
DFO group. The risk of experiencing persistent seizures
was lower with DFO compared with placebo (RR 0.80,
95% CI 0.67 to 0.95; 334 participants, one trial), but adverse
effects (including phlebitis and recurrent hypoglycaemia)
were more common with DFO (risk ratio for hypoglycae-
mia 1.48 (95% CI 0.97 to 2.26)) [134]. The adult trial com-
paring deferiprone with placebo found that the deferiprone
Maitland BMC Medicine  (2015) 13:42 Page 22 of 27group had significantly faster coma recovery and parasite
clearance [137]. No adverse effects were reported for this
trial. No evidence of benefit or harm overall was concluded
by Cochrane review [134].
Acidosis correction
N-acetylcysteine (NAC) has been proposed to lead to
correction of metabolic acidosis by its antioxidant effect
acting through direct scavenging of free radicals and re-
plenishment of glutathione and cysteine. NAC has also
been shown to have anti-parasitic effects [138]. Three
trials have examined effects of different doses as adjunct-
ive treatments to quinine or artesunate. The first, a small
placebo controlled trial of NAC in Thai adults (N = 15 in
each arm) had lactate clearance as the primary endpoint.
Lactic acidosis resolution was better at 24 hours in the
NAC group (10/15) than in the placebo group (3/15)
(P = 0.011), as was median coma resolution although
with wide variation and, thus, was non-significant. Need
for renal replacement therapy (two in each arm) or death
(arm in each arm) were similar [139]. A placebo con-
trolled trial of three different NAC dosage regimens given
in addition to artesunate had some methodological issues
since the key endpoints were not pre-specified; methods
of randomisation were not indicated and the study re-
quired patients to remain in hospital for 28 days. Few dif-
ferences were found in fever, parasitaemia clearance and
adverse medical events, although the reporting of these
was incomplete. There were only two deaths in the trial
indicating that the patients probably did not have severe
malaria [140]. A multisite double-blind placebo controlled
trial on the use of high dose intravenous NAC as adjunct-
ive treatment to artesunate in 108 adults in South East
Asia found that NAC had no significant effect on morta-
lity, lactate clearance times (P = 0.74) or coma recovery
times (P = 0.46). Parasite clearance time was increased but
largely attributable to differences in baseline parasitaemia,
nor did NAC have any effect on red cell deformability
properties [141]. In summary, despite some methodo-
logical concerns and the small size of the trials, the limited
data available from these do not provide justification for
further investigation of NAC as an adjunctive treatment.
Similarly, a lack of efficacy was found in another small
study of L-arginine; however, the results were not con-
clusive since the trial was halted early due to political in-
stability [142].
Fluid resuscitation, inotrope and and vasopressors: shock
and acidosis
Both dopamine and adrenaline (epinephrine) are used in
the management of infection-induced haemodynamic
shock as second line treatments when shock is refractory
to fluid boluses or when hypotension prevails [109]. Dopa-
mine has been used to improve mean arterial pressure(MAP) and cardiac output, primarily by increasing stroke
volume and heart rate and low dose therapy has been used
in the past to treat pre-renal acute kidney injury. Dopa-
mine however carries an increased risk of supraventricular
and ventricular arrhythmias. Adrenaline increases the
MAP since it is a powerful vasopressor agent, but in-
creases the risk of aerobic lactate production [109]. In
Vietnamese adults with severe sepsis (n = 10) and severe
malaria (n = 13), a crossover trial examining increasing
intravenous adrenaline infusion compared to increasing
dopamine doses found adrenaline and dopamine infusions
led to significant mean increases in cardiac index (which
was greater with adrenaline than dopamine), increased
MAP and a reduction in systemic vascular resistance.
However, inotropic doses of adrenaline resulted in the
development of lactic acidosis and falling pH and thus
curtailed the adrenaline dose-profile at some stage in
16 patients (84%). No significant differences were found
between sepsis and malaria subgroups with respect to
disease effects or responses to treatments [143]. Further
investigation of adrenaline was, therefore, not warranted.
Justification for investigating fluid resuscitation as an
adjunctive treatment in children with severe malaria
originated from the high mortality noted in association
with metabolic acidosis [27,67,144]. It was postulated
that in children with severe malaria complicated by me-
tabolic acidosis in accordance with other causes of pae-
daitric severe life threatening illness this is commonly
due to some degree of hypovolaemia [145], although this
view was controversial in severe malaria [146]. Prospect-
ive studies had identified markers of impaired perfusion
(delayed capillary refilling time, weak pulse, subnormal
systolic blood pressure and increased creatinine) in chil-
dren with metabolic acidosis as key correlates with poor
outcome [60]. Initial dose-finding studies in this sub-
group established that boluses of 20 to 40 ml/kg normal-
ised low central venous pressure, reduced tachycardia
and tachypnoea without adverse consequences [147] and
further studies established appropriate effects of fluid
therapy on myocardial performance [148]. In total, five
Phase II trials were conducted in Kenyan children with
severe malaria comparing different fluid types on phy-
siological endpoints, including correction of metabolic
acidosis (base excess) and haemodynamic parameters as
well as mortality and neurological sequelae in survivors.
The results of these trials are individually summarised in
Table 2 [60,149-152] but have been formally collated
(four of five) in a meta-analysis examining types of fluid
resuscitation therapy published in 2010 [153]. This re-
view compiled data from all published paediatric clinical
trials of fluid resuscitation. In the subgroup with malaria
these were the only four trials (none of which had a con-
trol arm), and all had similar designs, all showing com-
parable reductions in acidosis (the primary endpoint) as
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0.45% human albumin solution, 0.9% saline or Gelofu-
sine (a gelatin based colloid) [153]. When the mortality
data from all four trials were combined in the meta-
analysis this indicated that albumin significantly reduced
mortality (secondary endpoint) compared to either of the
other fluids (saline or Gelofusine), risk ratio 0.31 (95% CI
0.14 to 0.68) (P = 0.004). There was a non-significant
increase in neurological sequelae in survivors in those
treated with albumin 9/97 (9%) compared to other re-
suscitation fluids, 6/54 (6%) in saline and 1/37 (3%) in
gelofusine [153]. A further trial comparing Dextran 70
(D70) (n = 39) and 6% hydroxyethyl starch (HES) (n = 40)
found no difference in the primary outcome (shock re-
solution at eight hours) (D70: 23/37 (62%) versus HES:
25/39 (64%)), although resolution of acidosis was better in
the HES arm. Overall, case fatality (four in each arm, 5%)
was similar [152].
The Fluid Resuscitation as A Supportive Therapy trial
(FEAST) was conducted to provide evidence on the best
fluid management for children with shock and severe fe-
brile illness for doctors practicing in hospitals in resource-
limited settings [89]. FEAST was a multicenter three-arm
controlled trial comparing albumin bolus, and saline bolus
to no bolus control. FEAST was conducted at six centres
in three East African countries and involved 3,121 chil-
dren enrolled at the point of hospital admission. Shock
was defined pragmatically (incorporating parameters from
all the published paediatric shock definitions including
modest hypotension) and the controlled part of the trial
(FEAST A) only excluded children without severe hypo-
tension. Two major subgroups included in the trial were
those with severe sepsis (n = 1,330) and severe P. falcip-
arum malaria (n = 1,793). The data monitoring committee
stopped the trial early after enrollment of 3,141 of a pro-
jected 3,600 due to safety concerns. The primary endpoint,
48-hour mortality, was significantly worse in the two fluid
bolus arms, 111/1,050 (10.6%) in the albumin-bolus and
110/1,047 (10.5%) in the saline-bolus, compared to the
control (no bolus) 76/1,044 (7.3%); relative risk (95% CI)
any bolus versus control 1.45 (1.13 to 1.86, P = 0.003). Sec-
ondary endpoints including 28-day mortality were worse
in the bolus arms, 12% versus 8.7% in the control arm.
There was no difference between the treatment arms in
the number of adverse events (suspected pulmonary
oedema, brain swelling or allergic events). In the subgroup
with severe malaria, 48-hour mortality was 110/1,202
(9.2%) in the bolus arms compared to 34/591 (5.7%) in the
control (no bolus) arm, a relative risk of death of 1.59
(1.10 to 2.31). In all pre-specified sub-groups analysis,
there was no evidence of a benefit of fluid boluses [89]. In
a subsequent publication, early shock reversal at one hour
(responders), the central principle of the surviving sepsis
guidelines, was superior in the bolus arms compared tono bolus control (43% versus 32%, P <0.001). Despite this,
excess mortality with boluses was still evident in both ‘re-
sponders’ (relative risk 1.98 (0.94 to 4.17), P = 0.06), as well
as ‘non-responders’ at one hour (relative risk 1.67 (1.23 to
2.28), P = 0.001), with no evidence of heterogeneity (P =
0.68) [154]. Examining the terminal modes of death, the
major difference between bolus and control arms was the
higher proportion of cardiogenic shock in the bolus arms
(n = 123; 4.6% versus 2.6% in controls, P = 0.008), rather
than respiratory events or neurological terminal clinical
events [154]. A major issue raised following the publica-
tion of FEAST was whether the criteria used to define
shock in the trial were applicable to other guidelines, in-
cluding the WHO definition of shock. A further publica-
tion provided data to address this issue showing that of
the relatively limited number of children fulfilling the
WHO shock definition 48-hour mortality was 24/50 (48%)
in those receiving boluses compared to 3/15 (20%) in the
no-bolus control, an increased absolute risk of 28% and a
relative increase of 240% (P = 0.07 by two-sided Fisher’s
exact test). Moderate hypotension, consistent with many
definitions in paediatric shock, was also associated with
increased 48-hour mortality on boluses (an absolute risk
of 9.4% (‐2.6 to 21.4%)) [155].
A systematic review conducted after the FEAST trial
concluded that the majority of evidence from rando-
mised trials to date came from the FEAST trial and that
boluses significantly increased mortality of children in
shock, compared to those who did not receive boluses.
The evidence was considered to be of high quality and
sufficiently precise [156]. Prior to FEAST the evidence
supporting fluid resuscitation was reviewed in the 2008
Surviving Sepsis Campaign Guidelines which was in-
formed by a modified Delphi process, graded the current
paediatric recommendation (20 ml/kg boluses over five to
ten minutes up to 60 ml/kg) as 2C, indicating a weak rec-
ommendation with low quality of evidence [109,157]. The
systematic review concluded that withholding of bolus
fluids should be considered for populations similar to
those enrolled in FEAST and that there remained import-
ant questions about the extent to which these results are
applicable to other populations [156].
Transfusion
A Cochrane review including the only two African ran-
domised controlled trials (RCTs) [158,159] conducted
before 2000 (involving 114 and 116 children randomised
to blood transfusion or oral haematinics) concluded that
there was insufficient information on whether routinely
giving blood to clinically stable children with severe an-
aemia either reduces death or results in a higher haem-
atocrit measured at one month, and indicated the need
for a definitive trial [64]. Since then a recent trial has
evaluated the safety and efficacy of a higher volume of
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ume (20 ml/kg, n = 82) in Ugandan children which was
found to be safe and resulted in an accelerated hemato-
logical recovery in children with severe anaemia [160]. A
clinical trial is underway that is evaluating whether a
liberal rather than conservative transfusion strategy in
terms of a larger initial volume of transfused blood and
incorporating a higher threshold of haemoglobin of <6 g/dl
for transfusion will decrease both short and long term
mortality (TRACT trial: ISRCTN84086586).
Conclusions
In conclusion, human trials carried out on the basis of
pathophysiology studies, have so far made little progress
on reducing mortality, despite appearing to reduce mor-
bidity endpoints (such as convulsions, shock reversal or
improvements in acid base balance or cytokines); more
often than not, the supportive interventions have shown
harm. A new line of investigation that aims to disrupt
sequestration [161] looks promising and early phase trials
are planned. For the key risk factors for poor outcome –
coma, abnormal renal function, hypoglycaemia and acid-
osis – further studies and trials need to be conducted to
help us understand how best to treat these complications.
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